hydrogen carbonate and Rotavirus Infections

hydrogen carbonate has been researched along with Rotavirus Infections in 4 studies

Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.
hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.

Rotavirus Infections: Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.

Research

Studies (4)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Geometric Mean Concentration Using WC3 as the Viral Lysate

GMC of serum anti-rotavirus IgA antibodies as measured by enzyme linked immunosorbent assay (ELISA) using WC3 (heterologous to vaccine strain) as the viral lysate. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC 5D® and ROTAVAC®. (NCT03602053)
Timeframe: 28 day after last dose of the study vaccine

Geometric Mean Concentrations Using Strain 89-12 as the Viral Lysate

GMCs of serum anti-rotavirus IgA antibodies in each of the three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: 28 days after the last dose of a study vaccine.

Geometric Mean Fold Rise (GMFR) in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate

GMFR in each of the ROTAVAC 5D®, ROTAVAC® and Rotarix® vaccine arms. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: At 28 days after last dose of study vaccine in reference to baseline.

Geometric Mean Fold Rise (GMFR) Using Strain 89-12 as the Viral Lysate

GMFR in the three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: at 28 days after last dose of study vaccine in reference to baseline.

Immediate Adverse Events

Percentage of participants reporting immediate adverse events after each vaccination (NCT03602053)
Timeframe: within 30 minutes' post-vaccination.

Seroconversion Rate in Each of the Three Arms as Measured by ELISA Using WC3 as the Viral Lysate

"Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if a baseline concentration is < 20 U/mL or a post-vaccination serum anti-rotavirus IgA antibody concentration of ≥ 2-fold baseline level if a baseline concentration is ≥ 20 U/mL.~WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®." (NCT03602053)
Timeframe: 28 days after last dose of study vaccine.

Seroconversion Using Strain 89-12 as the Viral Lysate

Seroconversion rate in three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: 28 days after the last dose of a study vaccine.

Seropositivity Rate in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate

Seropositivity is defined as serum anti-rotavirus IgA antibody concentration ≥ 20 U/mL. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: 28 days after last dose of study vaccine

Seropositivity Using Strain 89-12 as the Viral Lysate

Seropositivity rate in three vaccine arms. 89-12 strain of Rotavirus used in the ELISA assay was homologous to Rotarix® and was heterologous to the strain contained in ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: at baseline and 28 days after last dose of study vaccine

Serious Adverse Events

Percentage of participants reporting SAEs (NCT03602053)
Timeframe: From first vaccination through 4 weeks after the last vaccination of each study participant. Immunogenicity

Seroresponse Rate in Each of the Three Vaccine Arms as Measured by ELISA Using WC3 as the Viral Lysate

Seroresponse will be assessed as a four-fold, three-fold and two- fold rise in antibody concentration from baseline. Seroresponse will be assessed as a four-fold, three-fold and two-fold rise in antibody concentration from baseline. WC3 strain of rotavirus used in the ELISA assay was heterologous to the 116E strain contained in the vaccines ROTAVAC® and ROTAVAC 5D®. (NCT03602053)
Timeframe: 28 days after last dose of study vaccine

Solicited Adverse Events

Percentage of participants reporting solicited post-vaccination reactogenicity (fever, diarrhea, vomiting, decreased appetite, irritability, decreased activity level) (NCT03602053)
Timeframe: 7 day period after each vaccination.

Unsolicited Adverse Events

Percentage of participants reporting unsolicited AEs at a rate >5%. (NCT03602053)
Timeframe: From first vaccination through 4 weeks after the last vaccination.

Reviews

1 review available for hydrogen carbonate and Rotavirus Infections

Trials

1 trial available for hydrogen carbonate and Rotavirus Infections

Other Studies

2 other studies available for hydrogen carbonate and Rotavirus Infections